Sobi has received FDA approval for Gamefant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in Still's disease. The approval is based on phase III data in which 54 percent of patients achieved a complete response at week 8. Gamifant is the first FDA-approved treatment for MAS and works by blocking gamma interferon. The drug is already approved for primary hemophagocytic lymphohistiocytosis (HLH).
|
Published June 30, 2025
Sobi receives FDA approval for Gamifant at MAS
Notes
Q-linea signs agreement with American trauma center
Diagonal Bio collaborates with SVA for coronavirus testing
SenzaGen secures order of SEK 1,3 million
Egetis carries out a directed share issue of SEK 183 million
Asker Healthcare acquires British Novus Med
BioLineRx and Hemispherian form joint venture for GLIX1
Mendus updates clinical strategy for vididencel
NEWSLETTER
Upcoming events
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
EU appears to be avoiding new US tariffs
How Sweden will attract more clinical trials
Novo and Lilly in battle over blood sugar, weight and heart health
Issue outcome signals recovery for biotech
Lobbying battle in the White House over Chinese medicines
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Today's news roundup
